Combination of Almonertinib & Concurrent Chemoradiotherapy in Unresectable

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05386888` - A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC	Phase 2
Recruiting	`NCT05128630` - Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.	Phase 2
Active, not recruiting	`NCT05027165` - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
Recruiting	`NCT04351256` - Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy	Phase 2
Active, not recruiting	`NCT04392505` - Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study	Phase 2
Recruiting	`NCT05611879` - Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC	Phase 2
Recruiting	`NCT05718297` - Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Phase 2
Not yet recruiting	`NCT06467383` - A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced
Recruiting	`NCT04830826` - A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
Recruiting	`NCT05757843` - Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab	Phase 2
Active, not recruiting	`NCT03999710` - Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT03454685` - The Role of Microbiota on the Development of Lung Cancer
Not yet recruiting	`NCT05177497` - SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC	Phase 2
Recruiting	`NCT04202809` - Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.	Phase 2
Recruiting	`NCT04585490` - Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	Phase 3
Recruiting	`NCT04654364` - Lung Cancer Registry
Recruiting	`NCT05344209` - Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer	Phase 2
Withdrawn	`NCT03130829` - To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC	N/A
Recruiting	`NCT04680377` - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients

NCT number	NCT04952168
Study type	Interventional
Source	Tongji Hospital
Contact	yuan Chen, MD
Phone	00862783663407
Email	chenyuan008@163.com
Status	Recruiting
Phase	Phase 2
Start date	June 2, 2021
Completion date	June 2, 2023

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms